Conti FF, et al. - Researchers ascertained the 36-month outcomes after the change from a fixed 24-month intravitreous aflibercept (Eylea; Regeneron, Tarrytown, NY) injections (IAI) dosing regimen to a routine clinical practice regimen in patients with neovascular age-related macular degeneration. They noted a gradual decline in these improvements when patients were transitioned to a variable regimen, despite the significant visual and anatomical gains noted in the 2 years of fixed-dosing IAI. Authors saw a nonsignificant decrease of -37.8 μm in central subfield thickness and a nonsignificant gain of 5.8 letters from baseline, at 36 months.